EPA Adds PFAS to CERCLA (Superfund) Law, Favoring Low-Waste Systems like BioLargo’s AEC

BioLargo’s PFAS treatment technology generates a fraction of the waste compared to carbon filtration

Westminster, CA – April 23, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today provided commentary on the importance of a final decision by the U.S. Environmental Protection Agency (EPA) to regulate two per- and polyfluoroalkyl substance (PFAS) chemicals as “hazardous substances” under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as the Superfund law. BioLargo’s PFAS treatment solution, the Aqueous Electrostatic Concentrator, generates a small fraction of the volume of PFAS-laden waste that carbon filtration systems generate, thus reducing operational costs of waste handling, transport, and disposal.

In the EPA press release, EPA Administrator Michael S. Regan stated, “Designating these chemicals under our Superfund authority will allow EPA to address more contaminated sites, take earlier action, and expedite cleanups, all while ensuring polluters pay for the costs to clean up pollution threatening the health of communities.” These new regulations come on the heels of the EPA’s announcement two weeks ago setting PFAS drinking water limits as low as four parts per trillion.

This new EPA action also means that these PFAS chemicals will be listed as “hazardous materials” under the Hazardous Materials Transportation Act, which will require materials containing these chemicals to be transported using special protocols.

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, Inc., which markets BioLargo’s PFAS treatment systems, commented, “We believe these and other upcoming regulations create a price advantage for our AEC system over competing sorbent technologies such as carbon filtration. With less waste generated, we can also offer clients waste handling all the way through to full destruction at our facility.”

These finalized CERCLA regulations are the most recent step by the EPA to limit exposure of Americans to PFAS. In addition to the recently announced federal drinking water standards for six PFAS chemicals, the agency also committed $9 billion in funding to help communities and water providers address contamination by PFAS and other emerging contaminants. This funding will assist communities and water providers to acquire PFAS monitoring and treatment systems to comply with new regulations.

Dennis P. Calvert, President and CEO of BioLargo, commented, “We’re pleased to see the U.S. government taking PFAS seriously and dedicating the billions of dollars in funding needed to protect municipal water supplies across the country.” 

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. Its website is www.biolargoequipment.com. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo PFAS Removal Technology Meets New US Drinking Water Standards

BioLargo’s Aqueous Electrostatic Concentrator generates a fraction of the waste product of competing technologies

Westminster, CA – April 15, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, confirmed that its Aqueous Electrostatic Concentrator (AEC) can remove per- and polyfluoroalkyl substances (PFAS) from water to meet and surpass the U.S. Environmental Protection Agency (EPA) drinking water limits for PFAS chemicals announced April 10, 2024. Additionally, the AEC produces far less PFAS-laden solid waste than carbon filtration or ion exchange, which should result in lower long-term costs for customers while reducing potential regulatory burden. BioLargo also offers advisory services, analytical testing, and education on PFAS science and regulations to water providers who need assistance complying with the new regulations. The newly finalized rules set national limits for PFAS in public drinking water to nearly undetectable levels, as low as 4 parts per trillion.

PFAS are an expansive group of man-made chemicals used for decades in the manufacture of countless goods, including non-stick cookware, fast-food containers, and firefighting foam. PFAS have been linked to numerous health problems including cancer and developmental issues, and are challenging to remove from water using traditional treatment techniques.

While traditional water filtration treatment technologies such as granular activated carbon, ion exchange, and membrane filtration may meet these new EPA standards on some PFAS species, they can fall short of achieving sufficient removal rates for short-chain PFAS molecules (such as the now-EPA-regulated GenX and PFHXS). They also have the significant downside of producing large volumes of PFAS-laden solid waste, which requires additional disposal costs and creates potential regulatory liability.

These new EPA regulations mark a shift in the evolving market for PFAS treatment technologies. Previously driven by a patchwork of state and local drinking water regulations, drinking water providers across the country will have to comply with the new federal standards. The EPA estimates compliance with the new rules will cost approximately $1.5 billion annually; spending in other industry segments is not included in that estimate (e.g., treatment of groundwater, wastewater, industrial wastewater, or landfill leachate).

“These long-awaited drinking water regulations are a big win for our technology,” commented Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, BioLargo’s water equipment subsidiary. “Our AEC has an edge over the competition, as it can meet these new standards for all PFAS contaminants and generates far less PFAS-laden waste requiring disposal.”

In addition to these new standards, in February 2024 the EPA proposed changes to the Resource Conservation and Recovery Act regulations by adding nine PFAS chemical compounds to its list of hazardous constituents in Title 40 of the Code of Federal Regulations Part 261 Appendix VIII.

“If these RCRA rules are finalized, costs associated with handling and disposing of PFAS-laden solid waste will likely become more expensive and difficult, giving our product a significant cost advantage over the competition,” said Ms. Chandler.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About BioLargo Equipment Solutions & Technologies

BioLargo Equipment Solutions & Technologies, Inc. sells and distributes sustainable, best-in-class water treatment systems that solve some of the toughest challenges in the modern water industry. From PFAS capture and destruction to water reuse technologies, every system delivers on a promise of uncompromising technical performance, sustainable energy usage and waste generation metrics, and clear ROI for operations that use them. Its website is www.biolargoequipment.com. BioLargo Equipment Solutions & Technologies, Inc. is a wholly owned subsidiary of BioLargo, Inc., a cleantech innovator and environmental engineering solutions provider dedicated to make life better through technological innovation.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo achieved 108% year-over-year revenue growth in 2023

Westminster, CA – April 2, 2024 – BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its Annual Report, filed April 1, 2024, showed the company’s annual revenues increased by 108% year-over-year compared to 2022 (www.biolargo.com/sec-filings).

BioLargo will hold an investor webcast on Tuesday, April 2, 2024, at 2:00 pm Pacific / 5:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/50271   

Dennis P. Calvert, the company’s President and CEO, commented, “Rising odor control product sales continue to push our business forward. We are confident that our PFAS solutions will find additional traction in 2024 and believe they will eventually contribute significantly to our overall growth trajectory. Almost cash-flow positive in the fourth quarter of 2023, we continue to focus our business on leveraging our intellectual property and partnering with great companies to scale up sales and distribution while preserving capital and human resources.”

The following are select highlights from BioLargo’s annual report filed April 1, 2024, and are not a substitute for the details in the 10-K, which can be found here (https://www.biolargo.com/sec-filings). All interested parties are encouraged to review the full report filed with the SEC, including the risk factors at page 9, to get the most complete information about BioLargo and its growing cleantech business.

Financial highlights from the annual report:

• Revenues for the year ended December 31, 2023, were $12,230,000, a 108% increase over 2022.
• Revenues in the fourth quarter of 2023 were $4,370,000, a 64% increase as compared with the third quarter of 2023 (quarter-over-quarter), and a 108% increase as compared with the fourth quarter of 2022.
• Cash flow from operations for the year was negative $2,365,000.
• The company’s net loss for the year ended December 31, 2023, was reduced by 9% as compared with the prior year, from $5,132,000 to $4,648,000. More than 60% of the company’s net loss was due to non-cash expenses, including $2,124,000 of stock option compensation expense, and $384,000 of services paid by the issuance of our common stock.
• 21% of the company’s total operating expenses in 2023 were from research and development, up from 16% in 2022, as we built out a facility to manufacture and test our first batteries.
• Total stockholders’ equity more than doubled - from $2,011,000 at December 31, 2022, to $4,202,000 at December 31, 2023.
• Total assets as of December 31, 2023 were $8,205,000, against total liabilities of $4,003,000.
• The company ended the year with working capital of $3,652,000.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

BioLargo Year-End 2023 Earnings Results Webcast and Conference Call on Tuesday, April 2, 2024 – 5:00 PM Eastern Time

Westminster, CA – April 1, 2024– BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Tuesday, April 2, 2024, at 2:00 pm Pacific / 5:00 pm Eastern. Open to the public, the webcast will be held to review the company’s financial results for the year ending December 31, 2023, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/50271

Teleconference Domestic: 877-545-0523

Teleconference International: 973-528-0016

Participant Access Code: 614240

To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration: Tuesday, July 02, 2024

Teleconference Replay Expiration: Tuesday, April 16, 2024

Teleconference Replay Domestic: 877-481-4010

Teleconference Replay International: 919-882-2331

Replay Passcode: 50271

The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations. 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.   

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.